• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.

作者信息

Schally A V, Redding T W, Paz-Bouza J I, Comaru-Schally A M, Mathe G

机构信息

Endocrine, Polypeptide and Cancer Institute, VA Medical Center, New Orleans, LA.

出版信息

Prog Clin Biol Res. 1987;243A:173-97.

PMID:2889215
Abstract
摘要

相似文献

1
Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.基于促黄体生成素释放激素（LH-RH）激动剂与其他药物联合使用来改善前列腺癌治疗的当前理念。
Prog Clin Biol Res. 1987;243A:173-97.
2
Current treatment of advanced prostate cancer.晚期前列腺癌的当前治疗方法。
Tech Urol. 1997 Spring;3(1):16-24.
3
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.前列腺特异性抗原（PSA）最低点不可检测水平可预测局部前列腺癌采用延迟联合雄激素阻断治疗时的PSA生化复发。
Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.
4
[Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].[最大雄激素阻断疗法治疗前列腺播散癌患者]
Vopr Onkol. 1998;44(5):537-40.
5
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
6
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.围绕晚期前列腺癌联合雄激素阻断疗法的二十年争议。
Cancer. 2009 Aug 1;115(15):3376-8. doi: 10.1002/cncr.24393.
7
Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.亮丙瑞林、曲普瑞林：新适应症。局部晚期前列腺癌：最低限度评估的仿制药。
Prescrire Int. 2007 Dec;16(92):243.
8
Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.氟他胺与[D-色氨酸6，去甘氨酰胺（10）]亮丙瑞林乙酯联合治疗C期和D期前列腺癌：当今的首选治疗方法——理论依据及5年临床经验
Prog Clin Biol Res. 1988;262:11-63.
9
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Clin Invest Med. 1993 Dec;16(6):493-8.
10
Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.生长抑素类似物与地塞米松（抗生存因子概念）联合促黄体生成素释放激素用于雄激素剥夺难治性伴骨转移的前列腺癌
BJU Int. 2007 Jul;100 Suppl 2:60-2. doi: 10.1111/j.1464-410X.2007.06958.x.

引用本文的文献

1
Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.促黄体生成素释放激素和生长抑素类似物治疗后实验性前列腺癌中催乳素、生长抑素和促黄体生成素释放激素的受体
Proc Natl Acad Sci U S A. 1988 Feb;85(3):890-4. doi: 10.1073/pnas.85.3.890.
2
Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.促黄体生成素释放激素强效拮抗剂对人乳腺肿瘤细胞生长的抑制作用
Proc Natl Acad Sci U S A. 1989 Mar;86(5):1648-51. doi: 10.1073/pnas.86.5.1648.
3
Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
使用促黄体生成素释放激素拮抗剂SB - 75的持续递送系统（微胶囊和微粒）抑制实验性前列腺癌的生长
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):844-8. doi: 10.1073/pnas.88.3.844.